Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
Comment
. 2013 Jul 2;110(27):10886-7.
doi: 10.1073/pnas.1308463110. Epub 2013 Jun 19.

Perspectives on anti-CD47 Antibody Treatment for Experimental Cancer

Affiliations
Free PMC article
Comment

Perspectives on anti-CD47 Antibody Treatment for Experimental Cancer

Emil R Unanue. Proc Natl Acad Sci U S A. .
Free PMC article

Conflict of interest statement

The author declares no conflict of interest.

Figures

Fig. 1.
Fig. 1.
(A) Macrophages ignore normal cells as a result of negative interactions in which the CD47–SIRP-α pair promote the “don’t eat me” signal. Cancer cells show high levels of CD47 and avoid phagocytosis despite having a higher level of calreticulin (12) (B), but blocking CD47 with antibody favors their uptake (C).

Comment on

Similar articles

See all similar articles

Cited by 3 articles

LinkOut - more resources

Feedback